AbbVie completes $8.75B note offering to fund Apogee acquisition
Less than 1 min read
AbbVie completed an $8.75 billion underwritten notes offering to fund part of its acquisition of Apogee Therapeutics.
Key Highlights:
- Issued $500M floating-rate notes due 2028 and $8.25B fixed-rate notes across maturities 2028–2066.
- Fixed coupons range from 4.500% (2028) to 6.100% (2066); notes are unsecured and pari passu with other senior debt.
- Net proceeds will fund cash consideration for the Apogee acquisition and related fees; remaining proceeds for general purposes.
- Certain shorter-dated series require special mandatory redemption if the Acquisition is terminated prior to closing.
Original SEC Filing: AbbVie Inc. [ ABBV ] - 8-K - Aug. 18, 2026
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.